Durable remission validation for CRISPR-Cure-7

Off-target edit surveillance in multi-pathway oncology CRISPR

Promising simulated market reaction, but standard-of-care claims require randomized data beyond a small Phase 1 cohort.

The patient enthusiasm signal is credible, but access, cost, and safety communication need equal weight.

Animates the prediction market moving from 65% to 78% as agents react to CRISPR-Cure-7 news.

Shows optimism and safety scrutiny pushing against each other during expert review.

Maps patient demand through reimbursement, manufacturing, and eligibility constraints.